ABVD chemotherapy in the treatment of Hodgkin's disease.
D000970:Antineoplastic Agents / Q000009:adverse effects; D001761:Bleomycin / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007938:Leukemia / Q000150:complications; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage*; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone